BB Biotech AG Amends IONIS PHARMACEUTICALS Stake
Ticker: IONS · Form: SC 13G/A · Filed: Feb 13, 2024 · CIK: 874015
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biotech, investor-update
TL;DR
**BB Biotech AG updated its IONIS PHARMACEUTICALS holding, signaling a potential shift in institutional investor sentiment.**
AI Summary
BB Biotech AG, a Swiss investment company, filed an amended Schedule 13G/A on February 13, 2024, indicating a change in its beneficial ownership of IONIS PHARMACEUTICALS INC common stock as of December 31, 2023. This filing, an amendment to a previous disclosure, signals that BB Biotech AG is part of a group holding these shares, which could imply a coordinated investment strategy. For investors, this matters because significant changes in institutional ownership can influence stock price and reflect a major investor's confidence (or lack thereof) in the company's future.
Why It Matters
Changes in major institutional holdings can signal shifts in investor sentiment or strategy, potentially impacting stock price and market perception of IONIS PHARMACEUTICALS INC.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of ownership and does not inherently indicate a high level of risk, though changes in ownership can influence market sentiment.
Analyst Insight
Investors should monitor future filings from BB Biotech AG and other institutional investors in IONIS PHARMACEUTICALS INC to identify any emerging trends in ownership that could signal shifts in market confidence.
Key Players & Entities
- BB Biotech AG (company) — the reporting person and filer of the SC 13G/A
- IONIS PHARMACEUTICALS INC (company) — the subject company whose common stock is being reported
- BIOTECH INVEST N.V. (company) — a group member associated with the filing
- Switzerland (company) — place of organization for BB Biotech AG
- December 31, 2023 (date) — date of event requiring the filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13)*' sections.
Who is the subject company of this filing?
The subject company is IONIS PHARMACEUTICALS INC, as indicated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC'.
Who is the reporting person making this filing?
The reporting person is BB Biotech AG, as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG' and 'Names of Reporting Persons BB Biotech AG'.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of IONIS PHARMACEUTICALS INC is 462222100, as listed under 'CUSIP No. 462222100'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified under 'December 31, 2023 (Date of Event Which Requires Filing This Statement)'.
Filing Stats: 863 words · 3 min read · ~3 pages · Grade level 9.5 · Accepted 2024-02-13 06:09:26
Key Financial Figures
- $0.001 — e of Class of Securities: Common Stock, $0.001 Par Value 2(e) CUSIP Number: 46222210
Filing Documents
- d749650dsc13ga.htm (SC 13G/A) — 46KB
- 0001193125-24-032788.txt ( ) — 48KB
SIGNATURES
SIGNATURES After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB Biotech AG Date: February 6, 2024 By: /s/ Martin Gubler Signatory Authority Name: Martin Gubler Title: Signatory Authority Date: February 6, 2024 By: /s/ Ivo Betschart Signatory Authority Name: Ivo Betschart Title: Signatory Authority Biotech Invest N.V. Date: February 6, 2024 By: /s/ Jan Bootsma Signatory Authority Name: Jan Bootsma Title: Signatory Authority Date: February 6, 2024 By: /s/ Hugo van Neutegem Signatory Authority Name: Hugo van Neutegem Title: Signatory Authority 5 of 6 Exhibit Index Exhibit A: Agreement by and between BB Biotech AG and Biotech Invest N.V. with respect to the filing of this disclosure statement.* * Previously filed as an exhibit to BB Biotech AG and Biotech Invest N.V.s Schedule 13G filed with the Securities and Exchange Commission on February 13, 2020. 6 of 6